Discontinued — last reported Q4 '22
Current Assets
Raw materials
Vertex Pharmaceuticals Raw materials increased by 25.8% to $278.60M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 97.4%, from $141.10M to $278.60M. Over 4 years (FY 2020 to FY 2024), Raw materials shows an upward trend with a 52.8% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryEfficiency
SignalContext dependent
VolatilityModerate
First reportedQ3 2017
Last reportedQ4 2022
Parent metricInventories
How to read this metric
High levels may signal proactive supply chain hedging against shortages, while low levels could indicate lean inventory management or potential supply risks.
Detailed definition
The cost of basic components and supplies held for use in the manufacturing of finished products. This inventory serves...
Peer comparison
Standard across manufacturing sectors; levels vary based on supply chain strategy and lead times.
Metric ID:
inv_raw_materialsHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $47.74M | $45.99M | $42.40M | $42.20M | $30.40M | $32.20M | $38.10M | $58.10M | $71.80M | $77.50M | $78.70M | $95.70M | $112.10M | $141.10M | $252.00M | $250.50M | $221.40M | $278.60M |
| QoQ Change | — | -3.7% | -7.8% | -0.5% | -28.0% | +5.9% | +18.3% | +52.5% | +23.6% | +7.9% | +1.5% | +21.6% | +17.1% | +25.9% | +78.6% | -0.6% | -11.6% | +25.8% |
| YoY Change | — | — | — | — | -36.3% | -30.0% | -10.1% | +37.7% | +136.2% | +140.7% | +106.6% | +64.7% | +56.1% | +82.1% | +220.2% | +161.8% | +97.5% | +97.4% |
| % of Inventories | 14.8% | 13.8% | 12.0% | 12.5% | 8.3% | 8.3% | 8.3% | 10.9% | 11.9% | 11.3% | 10.7% | 11.8% | 12.3% | 13.1% | 20.9% | 18.4% | 14.8% | 17.1% |
| Share Change | — | -1.1pp | -1.8pp | +0.4pp | -4.2pp | +0.0pp | -0.0pp | +2.6pp | +1.0pp | -0.6pp | -0.6pp | +1.1pp | +0.5pp | +0.8pp | +7.8pp | -2.5pp | -3.7pp | +2.4pp |
Range$30.40M – $278.60M
CAGR+51.4%
Avg YoY Growth+80.3%
Median YoY Growth+89.8%
Raw materials at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's raw materials?
- Vertex Pharmaceuticals (VRTX) reported raw materials of $278.60M in Q3 2025.
- How has Vertex Pharmaceuticals's raw materials changed year-over-year?
- Vertex Pharmaceuticals's raw materials increased by 97.4% year-over-year, from $141.10M to $278.60M.
- What is the long-term trend for Vertex Pharmaceuticals's raw materials?
- Over 4 years (2020 to 2024), Vertex Pharmaceuticals's raw materials has grown at a 52.8% compound annual growth rate (CAGR), from $46.23M to $252.00M.
- What does raw materials mean?
- The value of basic materials and supplies waiting to be used in production.